NCT07639983

Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-06-05Est. Completion: 2028-06-05

Enrollment target: 44 participants

Contact

Urothelial CancerUrinary Bladder Neoplasms

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder pre…

Santa Barbara, United StatesEst. completion Mar 31, 2030

Non-Muscle Invasive Bladder Neoplasms

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only hi…

Little Rock, United StatesEst. completion Nov 27, 2030

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.